<DOC>
	<DOCNO>NCT02909478</DOCNO>
	<brief_summary>Addition aprepitant , NK1 receptor antagonist 5-HT3 receptor antagonist dexamethasone regimen show effective prevention chemotherapy-induced nausea vomiting ( CINV ) moderately emetogenic chemotherapy ( MEC ) . Little known efficacy aprepitant use without dexamethasone . Dexamethasone widely use prevent acute delay nausea vomit induced chemotherapy . However , multi-period use dexamethasone could associate side effect , hyperglycemia , dyspepsia insomnia . This randomized phase III trial study antiemetic therapy aprepitant tropisetron see well work compare dexamethasone plus tropisetron prevent chemotherapy-induced nausea vomit patient colorectal cancer receive FOLFOX ( oxaliplatin , leuvovorin 5-fluorouracil ) chemotherapy .</brief_summary>
	<brief_title>Aprepitant Without Steroid Preventing Chemotherapy-induced Nausea Vomiting Patients With Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Tropisetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Diagnosis colorectal cancer No prior chemotherapy schedule receive FOLFOX chemotherapy ( oxaliplatin , leucovorin 5fluorouracil ) Age ≥18 year Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 2 Laboratory index : Hemoglobin ≥ 90 g/L ( No blood transfusion within 14 day ) , Absolute Neutrophil Count ≥ 1.5×10^9/L , Platelet Count ≥ 75×10^9/L , Serum Bilirubin ≤ 1.5×ULN , ALT AST ≤ 3.0×ULN ( without liver metastasis ) , ALT AST ≤ 5.0×ULN ( liver metastasis ) , Serum Creatinine ≤ 1×ULN , Endogenous Creatinine Clearance＞60ml/min Be able read , understand complete questionnaire diary Be able understand study procedure sign inform consent . Treatment study medicine within 4 week enrollment . Nausea vomit ≤ 24 hour prior registration Ongoing emesis due obstruction digestive tract Concurrent use olanzapine , phenothiazine amifostine Female pregnancy lactation Severe cognitive compromise Known history CNS disease ( e.g . brain metastasis , seizure disorder ) Concurrent abdominal radiotherapy Chronic alcoholism Known hypersensitivity aprepitant , tropisetron , dexamethasone . Known cardiac arrhythmia , uncontrolled congestive heart failure acute myocardial infarction within previous six month . History uncontrolled diabetes mellitus Serious uncontroled infection Known active HIV , viral hepatitis tuberculosis infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>